Cargando…
The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2
Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs). Elevated levels of CYP2J2 have been associated with various types of cancer, and therefore it serves as a potential drug target. Herein, using a high-throug...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946002/ https://www.ncbi.nlm.nih.gov/pubmed/33682565 http://dx.doi.org/10.1080/14756366.2021.1896500 |
_version_ | 1783662968886525952 |
---|---|
author | Tian, Xiangge Zhou, Meirong Ning, Jing Deng, Xiaopeng Feng, Lei Huang, Huilian Yao, Dahong Ma, Xiaochi |
author_facet | Tian, Xiangge Zhou, Meirong Ning, Jing Deng, Xiaopeng Feng, Lei Huang, Huilian Yao, Dahong Ma, Xiaochi |
author_sort | Tian, Xiangge |
collection | PubMed |
description | Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs). Elevated levels of CYP2J2 have been associated with various types of cancer, and therefore it serves as a potential drug target. Herein, using a high-throughput screening approach based on enzymic activity of CYP2J2, we rapidly and effectively identified a novel natural inhibitor (Piperine, 9a) with IC(50) value of 0.44 μM from 108 common herbal medicines. Next, a series of its derivatives were designed and synthesised based on the underlying interactions of Piperine with CYP2J2. As expected, the much stronger inhibitors 9k and 9l were developed and their inhibition activities increased about 10 folds than Piperine with the IC(50) values of 40 and 50 nM, respectively. Additionally, the inhibition kinetics illustrated the competitive inhibition types of 9k and 9l towards CYP2J2, and K(i) were calculated to be 0.11 and 0.074 μM, respectively. Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2. |
format | Online Article Text |
id | pubmed-7946002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-79460022021-03-22 The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 Tian, Xiangge Zhou, Meirong Ning, Jing Deng, Xiaopeng Feng, Lei Huang, Huilian Yao, Dahong Ma, Xiaochi J Enzyme Inhib Med Chem Research Paper Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs). Elevated levels of CYP2J2 have been associated with various types of cancer, and therefore it serves as a potential drug target. Herein, using a high-throughput screening approach based on enzymic activity of CYP2J2, we rapidly and effectively identified a novel natural inhibitor (Piperine, 9a) with IC(50) value of 0.44 μM from 108 common herbal medicines. Next, a series of its derivatives were designed and synthesised based on the underlying interactions of Piperine with CYP2J2. As expected, the much stronger inhibitors 9k and 9l were developed and their inhibition activities increased about 10 folds than Piperine with the IC(50) values of 40 and 50 nM, respectively. Additionally, the inhibition kinetics illustrated the competitive inhibition types of 9k and 9l towards CYP2J2, and K(i) were calculated to be 0.11 and 0.074 μM, respectively. Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2. Taylor & Francis 2021-03-07 /pmc/articles/PMC7946002/ /pubmed/33682565 http://dx.doi.org/10.1080/14756366.2021.1896500 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Tian, Xiangge Zhou, Meirong Ning, Jing Deng, Xiaopeng Feng, Lei Huang, Huilian Yao, Dahong Ma, Xiaochi The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title | The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title_full | The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title_fullStr | The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title_full_unstemmed | The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title_short | The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2 |
title_sort | development of novel cytochrome p450 2j2 (cyp2j2) inhibitor and the underlying interaction between inhibitor and cyp2j2 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946002/ https://www.ncbi.nlm.nih.gov/pubmed/33682565 http://dx.doi.org/10.1080/14756366.2021.1896500 |
work_keys_str_mv | AT tianxiangge thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT zhoumeirong thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT ningjing thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT dengxiaopeng thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT fenglei thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT huanghuilian thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT yaodahong thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT maxiaochi thedevelopmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT tianxiangge developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT zhoumeirong developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT ningjing developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT dengxiaopeng developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT fenglei developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT huanghuilian developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT yaodahong developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 AT maxiaochi developmentofnovelcytochromep4502j2cyp2j2inhibitorandtheunderlyinginteractionbetweeninhibitorandcyp2j2 |